By Sheeba M. | March 31, 2026
Cannabis Goes Global: Germany’s Legal Market Opens Doors for US MSOs
Germany’s cannabis reform went live on April 1, 2024 with personal cultivation and possession limits, but last week’s opening of licensed retail stores represents the commercial milestone the industry has been waiting for. Germany’s 83 million population and high per-capita cannabis consumption rates make it the most attractive new market for international operators in a decade.
Who’s Already Positioned
Curaleaf (CURLF) made the most aggressive early move, announcing a distribution partnership with German pharmaceutical distributor C生 World GmbH in Q3 2025. The partnership gives Curaleaf shelf placement in over 400 pharmacy-adjacent retail locations — a smart positioning play in a market where pharmacy access carries cultural legitimacy that pure dispensary retail lacks.
Organigram (OGI) has taken a different approach: direct investment in German cultivation startup Marihealth GmbH, retaining a 35% stake and a supply offtake agreement. This gives OGI production capacity inside the EU, potentially bypassing import regulatory friction that competitors will face.
Green Thumb Industries (GTBIF) has been quietest on European M&A, focusing instead on brand licensing conversations — allowing local operators to use GTBI cultivation technology and operating procedures under royalty arrangements. Lower capital commitment, but also lower floor on upside.
The Regulatory Landscape
Germany’s system differs meaningfully from U.S. state-level regulation. The Federal Institute for Drugs and Medical Devices (BfArM) oversees licensing, and cultivation licenses awarded so far have gone disproportionately to existing pharmaceutical companies with compliance infrastructure. This disadvantages U.S. MSOs that have cannabis expertise but less pharmaceutical regulatory experience.
EU GMP (Good Manufacturing Practice) certification is required for any cannabis products imported or produced for medical use — a standard most U.S. operators don’t currently hold. For adult-use products, the requirements are lighter, but the regulatory learning curve is steep for operators accustomed to U.S. state compliance frameworks.
Market Size Projections
German market modeling from BDSA (now part of Prohibition Partners) projects the adult-use market reaching €4.2 billion annually by 2028, with medical cannabis growing to €1.8 billion. These numbers assume retail availability similar to alcohol distribution — which remains contested politically and may take 2-3 years to fully materialize.
The near-term opportunity is medical cannabis: Germany’s medical program already has over 200,000 registered patients, and retail store openings have increased medical dispensations as doctor awareness grows. For operators with pharmaceutical-grade products and EU GMP certification, this is the fastest path to revenue.
The Canada Comparison
Canadian LPs that entered the U.S. market in 2018-2019 learned a hard lesson: state-level regulation and vertical integration requirements meant that Canadian operational playbooks didn’t translate cleanly. U.S. MSOs entering Germany risk making the mirror-image mistake — assuming U.S. cannabis expertise transfers to a pharmaceutical regulatory environment with fundamentally different compliance demands.
The operators most likely to succeed in Germany are those treating it as a separate business unit with dedicated leadership, local regulatory counsel, and realistic 3-5 year return expectations rather than trying to bolt European operations onto existing U.S. infrastructure.
Sources
- Prohibition Partners – European Cannabis Report Q1 2026
- BfArM – German Federal Institute for Drugs and Medical Devices cannabis licensing
Track These Stocks
Track cannabis stocks with the Weedstock Real-Time Tracker